Tracking blood markers in locally advanced cervical cancer after chemoradiotherapy
Observes blood tumor DNA and HPV levels in women with cervical cancer after chemoradiotherapy.
Plain-language title generated from the registry record
Registry title: Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
Key facts
- Where
- Guiyang, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 75 with cervical cancer confirmed by tissue examination, who are having concurrent chemoradiotherapy.
- Age
- 18 to 75 years
- Sex
- Women only
- Disease stage
- Cervical cancer confirmed by tissue examination (locally advanced); a lesion that can be measured before treatment; ECOG score 0-1 (or KPS score 70-100); expected survival of at least 6 months.
- Earlier treatment
- If the patient has syphilis, treatment for it is needed before this treatment.
Main reasons for not taking part
- Allergy to rubber products
- Severe acute infection, hepatitis B in active stage, active tuberculosis, syphilis outbreak or AIDS
- Severe heart disease
- Uncontrolled nerve or mental illness, or brain tumor or spread to the central nervous system
- Already taking part in other clinical trials
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05950087, who can take part
Where in China
- Yong LiGuiyang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Guizhou Provincial People's Hospital
- Trial code
- NCT05950087
- Record updated
- 18 July 2023
- Original description
Cervical cancer CC is the most common malignant tumor in the female reproductive system, seriously endangering women's health and life, and is one of the leading causes of death for women worldwide.Globally, HPV causes about 85% of cervical cancers and about 60% of oropharyngeal cancers, causing more than 500,000 cancers each year.ctDNA is a potential biomarker because it contains tumor-specific genetic and epigenetic abnormalities that can be used in cancer diagnosis and prognosis prediction.MRD is considered a promising prognostic marker that can be used to identify individuals at increased risk of recurrence and individuals who may benefit from treatment.The expression level of MRD and plasma HPV before and after radiotherapy and chemotherapy for cervical cancer was analyzed by liquid biopsy ctDNA detection technology, which predicted the efficacy of cervical cancer radiotherapy and chemotherapy, which was helpful for monitoring and estimating the risk of disease recurrence after cervical cancer radiotherapy and chemotherapy, and verified the expression of MRD and plasma HPV as the basis for adjuvant chemotherapy after cervical cancer radiotherapy and the basis for optimal chemotherapy time node selection.Read full original descriptionShow less
Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
Cervical cancer CC is the most common malignant tumor in the female reproductive system, seriously endangering women's health and life, and is one of the leading causes of death for women worldwide.Globally, HPV causes about 85% of cervical cancers and about 60% of oropharyngeal cancers, causing more than 500,000 cancers each year.ctDNA is a potential biomarker because it contains tumor-specific genetic and epigenetic abnormalities that can be used in cancer diagnosis and prognosis prediction.MRD is considered a promising prognostic marker that can be used to identify individuals at increased risk of recurrence and individuals who may benefit from treatment.The expression level of MRD and plasma HPV before and after radiotherapy and chemotherapy for cervical cancer was analyzed by liquid biopsy ctDNA detection technology, which predicted the efficacy of cervical cancer radiotherapy and chemotherapy, which was helpful for monitoring and estimating the risk of disease recurrence after cervical cancer radiotherapy and chemotherapy, and verified the expression of MRD and plasma HPV as the basis for adjuvant chemotherapy after cervical cancer radiotherapy and the basis for optimal chemotherapy time node selection.
Inclusion: Age: ≥ 18 years old, ≤ 75 years old; Pathological histologic confirmation of cervical cancer; Imaging or PET/CT examination can be performed to understand the tumor and complete all follow-up; Measurable lesions before treatment; Good physical condition: ECOG score 0-1 (or KPS score 70-100); Estimated survival≥ 6 months; The baseline blood routine and biochemical indexes before radiotherapy and chemotherapy met the following standards: hemoglobin ≥ 80g/L, absolute neutrophil count (ANC) ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT, AST ≤ 2.5 times the normal upper limit; Serum albumin ≥ 30 g/L; There are three preoperative items: if the patient has syphilis, plum repellent therapy is required before treatment; The patient has no history of allergy to rubber products; Cardiopulmonary function is basically normal.
Exclusion: Those who are allergic to rubber products; Those with severe acute infection and uncontrolled or purulent and chronic infection wounds that do not heal, chronic hepatitis B active stage, active tuberculosis, syphilis outbreak and AIDS; Patients with pre-existing severe heart disease, including: congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and intractable hypertension; Those with neurological or psychiatric diseases or mental disorders that are not easy to control, poor compliance, unable to cooperate with and describe treatment responses, uncontrolled primary brain tumors or central nervous system metastases, and those with obvious cranial hypertension signs or neuropsychiatric symptoms; with malignant serous effusion; History of severe enteritis and cystitis, bleeding, intestinal perforation, rectovaginal fistula, rectoval bladder fistula, etc; Those who have participated in other clinical trials; Other situations in which the investigator believes that the subject is not suitable to participate in this experiment.